These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19088048)

  • 1. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
    Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
    Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
    PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
    Banerji U; Affolter A; Judson I; Marais R; Workman P
    Mol Cancer Ther; 2008 Apr; 7(4):737-9. PubMed ID: 18375819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
    Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
    Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.
    Fukuyo Y; Inoue M; Nakajima T; Higashikubo R; Horikoshi NT; Hunt C; Usheva A; Freeman ML; Horikoshi N
    Cancer Res; 2008 Aug; 68(15):6324-30. PubMed ID: 18676857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
    Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
    Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
    Marunouchi T; Nakashima M; Ebitani S; Umezu S; Karasawa K; Yano E; Tanonaka K
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):822-829. PubMed ID: 34016843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D; Marshall JC; Antecka E; Di Cesare S; Odashiro AN; Bakalian S; Fernandes BF; Burnier MN
    Clin Cancer Res; 2008 Feb; 14(3):847-55. PubMed ID: 18245548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.